OncLive TV

Dr Sieber on the Importance of Evaluating Comorbidities in Prostate Cancer Prior to ADT

August 3rd 2023

Paul Sieber, MD, discusses the importance of evaluating comorbidities in patients with prostate cancer, including assessing risk factors for cardiovascular events in those who are initiating androgen deprivation therapy.

Dr Mohty on the Promise of Elranatamab in Relapsed/Refractory Multiple Myeloma

August 3rd 2023

Mohamad Mohty, MD, PhD, discusses the promise of the phase 2 MagnetisMM-3 trial in patients with relapsed/refractory multiple myeloma, which is investigating elranatamab monotherapy in this patient population.

Dr Khan on the Effects of Financial Toxicity on Survival Outcomes in Patients With Cancer

August 3rd 2023

Hiba Khan, MD, MPH, discusses how adverse financial events may contribute to the risk of early mortality in patients with cancer.

Dr Kim on the Bridging the Gaps in Lung Cancer Meeting

August 3rd 2023

Edward S. Kim, MD, MBA, discusses the importance of the Bridging the Gaps in Lung Cancer meeting, and expands on the importance of educating clinicians on how to best implement new developments within lung cancer to address these gaps in care.

Dr Ziegler on Tovorafenib in Pediatric Low-Grade Glioma

August 2nd 2023

David Ziegler, MD, PhD, discusses findings from the phase 2 FIREFLY-1 trial of tovorafenib in pediatric patients with low-grade glioma.

Dr Bhatnagar on Survival Outcomes With MRD Negativity in AML

August 2nd 2023

Bhavana “Tina” Bhatnagar, DO, discusses the investigation of minimal residual disease negativity in patients with acute myeloid leukemia.

Dr Danish on the Potential Use of SCINTIX Radiation Technology in Bone and Lung Tumors

August 2nd 2023

Adnan F. Danish, MD, discusses the methodologies behind the use of SCINTIX radiation technology in metastatic bone and lung tumors, detailing how this technology differs from computed tomography or magnetic resonance imaging scans prior to treatment.

Dr Abdou on Considerations Between AKT vs PI3K Inhibition in HR+/HER2– Breast Cancer

August 2nd 2023

Yara Abdou, MD, discusses the considerations between AKT inhibitors vs PI3K inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.

Dr Islam on Updated Safety and Efficacy Data With FDA-Approved BTK Inhibitors in CLL

August 2nd 2023

Prioty Islam, MD, MSc, discusses the impact of the updated safety and efficacy data seen with FDA-approved BTK inhibitors in patients with chronic lymphocytic leukemia.

Dr Das on the Landscape of Current and Emerging ADCs in SCLC

August 2nd 2023

Millie Das, MD, discusses the current landscape of new and emerging ADCs under investigation in small-cell lung cancer and highlights the phase 2 SWOG S1929 study.

Dr Lau on the Temportal Patterns of irAEs Associated With the Stride Regimen in HCC

August 2nd 2023

George Lau, MD, FRCP, FAASLD, discusses clinical implications for the use of dual checkpoint inhibition in HCC based on an analysis of immune-related adverse effects seen with the STRIDE regimen in the phase 3 HIMALAYA trial.

Dr Taieb on the FDA Approval of TAS-102 Plus Bevacizumab in mCRC

August 2nd 2023

Franklin on the Investigation of Social Needs and Screening Rates in CRC

August 1st 2023

Isabelle Franklin, discusses the investigation of the correlation between self-reported social needs and colorectal cancer screening.

Dr Costa on the Background of the MASTER Trial in Newly Diagnosed Multiple Myeloma

August 1st 2023

Luciano J. Costa, MD, PhD, discusses the background of the phase 2 MASTER trial in newly diagnosed multiple myeloma.

Dr Islam on Clinical Decisions Regarding BTK Inhibitor Use in MCL and CLL

August 1st 2023

Prioty Islam, MD, MSc, discusses the importance of shared decision making between patients and clinicians when selecting among available BTK inhibitors in the treatment of chronic lymphocytic leukemia or mantle cell lymphoma.

Dr Sun on Ongoing Research Efforts Examining Clonal Hematopoiesis in RCC

July 31st 2023

Maxine Sun, PhD, MPH, discusses ongoing research efforts dedicated to examining the relationship between clonal hematopoiesis and cardiovascular disease in patients with renal cell carcinoma.

Dr Sonpavde on the Results of the SWOG S1011 Trial in MIBC

July 31st 2023

Guru P. Sonpavde, MD, discusses results from the phase 3 SWOG S1011 trial conducted in patients with muscle-invasive bladder cancer.

Dr Abdou on Treatment Updates From the 2023 ASCO Annual Meeting in HR+/HER2– Breast Cancer

July 31st 2023

Yara Abdou, MD, discusses updates in the treatment of patients with HR-positive, HER2-negative breast cancer.

Dr Mirza on the FDA Approval of Dostarlimab Plus Chemotherapy in dMMR/MSI-H Endometrial Cancer

July 31st 2023

Mansoor Raza Mirza, MD, discusses the significance of the FDA approval of dostarlimab in combination with chemotherapy in patients with mismatch repair–deficient or microsatellite instability–high endometrial cancer.

Dr Hitchcock on Potential Clinical Implications of the ERAsur Trial in Limited mCRC

July 31st 2023

Kathryn Hitchcock, MD, PhD, expands on potential clinical implications of the ongoing phase 3 ERAsur trial in metastatic colorectal cancer